The company’s follow-up drug Skyrizi is a key plank in AbbVie’s strategy to negotiate the $20 billion patent cliff from Humira, which has already seen sales decline outside of the US where it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback